Rana Ezzeddine

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani et al. · Blood · 2006 · 609 citations · Full text

Medicine, Hematology, Oncology +14

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2013 · 596 citations · Full text

Medicine, Oncology, Pharmacology +13

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 354 citations

Medicine, Hematology, Oncology +13

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

Henri Roché, Louise Yelle, Francesco Cognetti et al. · Journal of Clinical Oncology · 2007 · 225 citations

Medicine, Oncology, Pharmacology +16